18F-FDG PET/CT characteristics of IASLC grade 3 invasive adenocarcinoma and the value of 18F-FDG PET/CT for preoperative prediction

Hanyun Yang; Xinran Liu; Lijuan Wang; Wenlan Zhou; Ying Tian; Ye Dong; Kemin Zhou; Li Chen; Meng Wang; Hubing Wu

doi:10.1101/2023.10.04.23296555

Abstract

Purpose This study is performed to investigate the imaging characteristics of the International Association for the study of lung cancer (IASLC) grade 3 invasive adenocarcinoma (IAC) on PET/CT and the value of PET/CT for preoperative predicting this tumor.

Materials and Methods We retrospectively enrolled patients with IAC from August 2015 to September 2022. The clinical characteristics, serum tumor markers, and PET/CT features were analyzed. T test, Mann-Whitney U test, χ² test, Logistic regression analysis, and receiver operating characteristic (ROC) analysis were used to predict grade 3 tumor and evaluate the prediction effectiveness.

Results Grade 3 tumors had a significantly higher maximum standardized uptake value (SUV_max) (P < 0.001), while Grade 1 - 2 tumors were prone to present with air bronchogram sign or vacuole sign (P < 0.001). Multivariate logistic regression analysis revealed that only SUV_max (OR = 1.137; 95% CI: 1.037, 1.247; P < 0.05) and air bronchogram sign or vacuole sign (OR = 0.225; 95% CI: 0.088, 0.572; P < 0.05) were independent predictors for Grade 3 tumors. The established prediction formula for Grade 3 tumors was P = one / [one + EXP (1.112 - 0.187 × SUV_max + 1.395 × air bronchogram sign or vacuole sign)], which generated a high AUC (0.825) and negative predictive value (0.924), respectively.

Conclusion Our study demonstrates that grade 3 IAC has a unique PET/CT imaging feature. The prediction model established with SUV_max and air bronchogram sign or vacuole sign can effectively predict grade 3 tumors before the operation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Natural Science Foundation of China [grant numbers 82171984].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of Nanfang Hospital,Southern Medical University waived ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes